EGFR Protein, Human (621a.a, CHO, His)

EGFR is a transmembrane glycoprotein. EGFR binds to ligands, triggering receptor dimerization, inducing intracellular TK domain autophosphorylation, activating downstream Ras/MAPK, PI3K/Akt and other signaling pathways, and regulating cell proliferation, survival, migration and angiogenesis. EGFR Protein, Human (621a.a, CHO, His) is a recombinant EGFR protein expressed by CHO, with a C-His tag and glycosylation modification^[1][3][4][5].

EGFR belongs to the epidermal growth factor receptor family. EGFR is a transmembrane glycoprotein. EGFR has an extracellular domain of 621 amino acids, a single transmembrane domain of 23 amino acids, and an enzymatically active intracellular domain of 542 amino acids. EGFR binds to its ligand, triggers receptor dimerization, induces autophosphorylation of the intracellular TK domain, activates downstream Ras/MAPK, PI3K/Akt and other signaling pathways, and regulates cell proliferation, survival, migration and angiogenesis. EGFR is expressed in a variety of normal epithelial tissues and tumor tissues, such as breast, lung, stomach, colon, head and neck, and its abnormal expression is associated with the malignant progression of tumors^{[1][2][3][4][5][6]}.

1.This product does not contain protein kinase domain.
2.The ED₅₀ is <1 μg/mL as measured in a cell proliferation assay by 3T3 cells in the presence of 25 pg/ml human EGF.
3.Immobilized EGFR Protein, Human can bind Petosemtamab (HY-P99406). The EC₅₀ for this effect is 4.45 ng/mL.

• 
  Immobilized EGFR Protein, Human can bind Petosemtamab (HY-P99406). The EC₅₀ for this effect is 4.45 ng/mL.

Human

CHO

C-His

P00533-1 (L25-S645)

1956  [NCBI]

Extracellular Domain

LEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPS

95-115 kDa

≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Lemmon M A, et al. Cell signaling by receptor tyrosine kinases. Cell, 2010, 141(7): 1117-1134.

  [2]. Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol. 2005 Apr;16(4):538-48.  [Content Brief]

  [3]. Yarden Y, et al. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37.  [Content Brief]

  [4]. Shepard HM, et al. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest. 2008 Nov;118(11):3574-81.  [Content Brief]

  [5]. Okines A, et al. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol. 2011 Apr 5;8(8):492-503.  [Content Brief]

  [6]. Ho ECH, et al. Characterization of monoclonal antibodies generated to the 287-302 amino acid loop of the human epidermal growth factor receptor'. Antib Ther. 2019 Oct;2(4):88-98.  [Content Brief]